238 related articles for article (PubMed ID: 21183291)
1. Hypofractionation results in reduced tumor cell kill compared to conventional fractionation for tumors with regions of hypoxia.
Carlson DJ; Keall PJ; Loo BW; Chen ZJ; Brown JM
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1188-95. PubMed ID: 21183291
[TBL] [Abstract][Full Text] [Related]
2. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the alpha/beta ratio.
Nahum AE; Movsas B; Horwitz EM; Stobbe CC; Chapman JD
Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):391-401. PubMed ID: 12957250
[TBL] [Abstract][Full Text] [Related]
3. Can drugs enhance hypofractionated radiotherapy? A novel method of modeling radiosensitization using in vitro data.
Ohri N; Dicker AP; Lawrence YR
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):385-93. PubMed ID: 22265460
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic ablative radiotherapy in the framework of classical radiobiology: response to Drs. Brown, Diehn, and Loo.
Meyer J; Timmerman R
Int J Radiat Oncol Biol Phys; 2011 Apr; 79(5):1599-600; author reply 1600. PubMed ID: 21414517
[No Abstract] [Full Text] [Related]
5. Stochastic Predictions of Cell Kill During Stereotactic Ablative Radiation Therapy: Do Hypoxia and Reoxygenation Really Matter?
Harriss-Phillips WM; Bezak E; Potter A
Int J Radiat Oncol Biol Phys; 2016 Jul; 95(4):1290-7. PubMed ID: 27212197
[TBL] [Abstract][Full Text] [Related]
6. Changes in tumor oxygenation during combined treatment with split-course radiotherapy and chemotherapy in patients with head and neck cancer.
Stadler P; Feldmann HJ; Creighton C; Kau R; Molls M
Radiother Oncol; 1998 Aug; 48(2):157-64. PubMed ID: 9783887
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-inducible factor pathway inhibition resolves tumor hypoxia and improves local tumor control after single-dose irradiation.
Helbig L; Koi L; Brüchner K; Gurtner K; Hess-Stumpp H; Unterschemmann K; Pruschy M; Baumann M; Yaromina A; Zips D
Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):159-66. PubMed ID: 24331663
[TBL] [Abstract][Full Text] [Related]
8. Clinical oxygen enhancement ratio of tumors in carbon ion radiotherapy: the influence of local oxygenation changes.
Antonovic L; Lindblom E; Dasu A; Bassler N; Furusawa Y; Toma-Dasu I
J Radiat Res; 2014 Sep; 55(5):902-11. PubMed ID: 24728013
[TBL] [Abstract][Full Text] [Related]
9. Optimal radiotherapy for prostate cancer: predictions for conventional external beam, IMRT, and brachytherapy from radiobiologic models.
King CR; DiPetrillo TA; Wazer DE
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(1):165-72. PubMed ID: 10656389
[TBL] [Abstract][Full Text] [Related]
10. Dynamic optimization of a linear-quadratic model with incomplete repair and volume-dependent sensitivity and repopulation.
Wein LM; Cohen JE; Wu JT
Int J Radiat Oncol Biol Phys; 2000 Jul; 47(4):1073-83. PubMed ID: 10863081
[TBL] [Abstract][Full Text] [Related]
11. Hypoxic sensitizer and cytotoxin for head and neck cancer.
Lee DJ; Moini M; Giuliano J; Westra WH
Ann Acad Med Singap; 1996 May; 25(3):397-404. PubMed ID: 8876907
[TBL] [Abstract][Full Text] [Related]
12. Hypofractionation: what does it mean for prostate cancer treatment?
Liao Y; Joiner M; Huang Y; Burmeister J
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):260-8. PubMed ID: 19879698
[TBL] [Abstract][Full Text] [Related]
13. Volume effects in the TCP for hypoxic and oxygenated tumors.
Chvetsov AV; Stewart RD; Kim M; Meyer J; Rengan R
Med Phys; 2020 Sep; 47(9):4626-4633. PubMed ID: 32452034
[TBL] [Abstract][Full Text] [Related]
14. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
15. Expression of EGFR under tumor hypoxia: identification of a subpopulation of tumor cells responsible for aggressiveness and treatment resistance.
Hoogsteen IJ; Marres HA; van den Hoogen FJ; Rijken PF; Lok J; Bussink J; Kaanders JH
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):807-14. PubMed ID: 22420963
[TBL] [Abstract][Full Text] [Related]
16. Changes in the fraction of total hypoxia and hypoxia subtypes in human squamous cell carcinomas upon fractionated irradiation: evaluation using pattern recognition in microcirculatory supply units.
Maftei CA; Bayer C; Shi K; Astner ST; Vaupel P
Radiother Oncol; 2011 Oct; 101(1):209-16. PubMed ID: 21641070
[TBL] [Abstract][Full Text] [Related]
17. A radiobiological model of reoxygenation and fractionation effects.
Guerrero M; Carlson DJ
Med Phys; 2017 May; 44(5):2002-2010. PubMed ID: 28273349
[TBL] [Abstract][Full Text] [Related]
18. Theoretical effectiveness of cell survival in fractionated radiotherapy with hypoxia-targeted dose escalation.
Chvetsov AV; Rajendran JG; Zeng J; Patel SA; Bowen SR; Kim EY
Med Phys; 2017 May; 44(5):1975-1982. PubMed ID: 28236652
[TBL] [Abstract][Full Text] [Related]
19. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy.
Miralbell R; Roberts SA; Zubizarreta E; Hendry JH
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):e17-24. PubMed ID: 21324610
[TBL] [Abstract][Full Text] [Related]
20. Endogenous markers of tumor hypoxia predictors of clinical radiation resistance?
Vordermark D; Brown JM
Strahlenther Onkol; 2003 Dec; 179(12):801-11. PubMed ID: 14652668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
